Karyopharm Therapeutics, Inc. (KPTI)
8.22
-0.46
(-5.30%)
USD |
NASDAQ |
Jan 12, 16:00
8.20
-0.02
(-0.24%)
After-Hours: 20:00
Karyopharm Therapeutics Research and Development Expense (Quarterly): 30.42M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Bruker Corp. | 98.30M |
| TG Therapeutics, Inc. | 40.88M |
| Actinium Pharmaceuticals, Inc. | 4.042M |
| Axsome Therapeutics, Inc. | 40.04M |
| Krystal Biotech, Inc. | 13.18M |